Ruxolitinib for graft-versus-host disease after transplant
Treatments studied
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This trial tests a drug called ruxolitinib for treating acute graft-versus-host disease (aGVHD), a common complication after a stem cell transplant. It may help control the immune reaction without using high doses of steroids.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have acute GVHD that is either standard risk or high risk as defined by your doctor.
- You have not received any prior systemic treatment for acute GVHD (topical or non-absorbed steroids are okay).
- Your blood counts are adequate: neutrophils at least 500-1000 and platelets at least 20,000 (with support if needed).
- You are 18 years or older.
- You have not taken ruxolitinib or similar drugs within the last 7 days or ever for GVHD.
- You do not have uncontrolled infections, severe organ failure, or relapsed cancer requiring immunosuppression withdrawal.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether the drug ruxolitinib, given based on a blood test that predicts risk, can prevent chronic graft-versus-host disease (cGVHD) after a stem cell transplant. It may help people who have a higher risk of developing this complication.
This trial tests whether starting ruxolitinib early, guided by a blood marker, can prevent acute graft-versus-host disease (aGVHD) after a stem cell transplant. It's for people who have already had a transplant and are at risk for this complication.
This study looks at how well a medicine called ruxolitinib works for patients with graft-versus-host disease (GVHD)—a condition where donor cells attack your body after a bone marrow or stem cell transplant. The trial aims to understand if ruxolitinib can help control this side effect.
This trial tests whether the drug ruxolitinib, given before and after a stem cell transplant, can help prevent graft-versus-host disease (GVHD) in people with blood cancers. GVHD is a common complication where donor cells attack the patient's body.
This trial tests whether adding ruxolitinib to standard steroid treatment works better than steroids alone for people with moderate to severe chronic graft-versus-host disease (cGVHD). cGVHD is a condition where donor immune cells attack the body after a stem cell transplant.
This trial tests new medications for people who develop severe acute graft-versus-host disease (aGVHD) within 100 days after their first stem cell transplant. The goal is to find safer, more effective ways to control aGVHD and improve recovery.
Hear when a new Acute Graft Versus Host Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.